These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 10090953

  • 1. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
    Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R.
    Blood; 1999 Apr 01; 93(7):2411-9. PubMed ID: 10090953
    [Abstract] [Full Text] [Related]

  • 2. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
    Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Engleman EG, Blume KG, Levy R.
    Biol Blood Marrow Transplant; 2000 Apr 01; 6(6):621-7. PubMed ID: 11128812
    [Abstract] [Full Text] [Related]

  • 3. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
    Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice V, Di Bello C, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM.
    Br J Haematol; 2007 Nov 01; 139(3):415-24. PubMed ID: 17910631
    [Abstract] [Full Text] [Related]

  • 4. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
    Reichardt VL, Milazzo C, Brugger W, Einsele H, Kanz L, Brossart P.
    Haematologica; 2003 Oct 01; 88(10):1139-49. PubMed ID: 14555310
    [Abstract] [Full Text] [Related]

  • 5. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
    Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A.
    Blood; 1999 Jul 15; 94(2):673-83. PubMed ID: 10397734
    [Abstract] [Full Text] [Related]

  • 6. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
    Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S, Cottler-Fox M, Barlogie B, Tricot G, van Rhee F.
    Br J Haematol; 2010 Sep 15; 150(5):554-64. PubMed ID: 20618329
    [Abstract] [Full Text] [Related]

  • 7. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
    Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, Orfao A.
    Leuk Lymphoma; 2006 Jan 15; 47(1):29-37. PubMed ID: 16321824
    [Abstract] [Full Text] [Related]

  • 8. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R.
    Blood; 2002 Mar 01; 99(5):1517-26. PubMed ID: 11861263
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
    Lim SH, Bailey-Wood R.
    Int J Cancer; 1999 Oct 08; 83(2):215-22. PubMed ID: 10471530
    [Abstract] [Full Text] [Related]

  • 11. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
    Zeis M, Frenzke H, Schmitz N, Uharek L, Steinmann J.
    Bone Marrow Transplant; 2002 Feb 08; 29(3):213-21. PubMed ID: 11859393
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
    Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M.
    Leukemia; 2004 Jan 08; 18(1):139-45. PubMed ID: 14574332
    [Abstract] [Full Text] [Related]

  • 14. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
    Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, Carsten C, Diehl V, Bohlen H.
    Br J Haematol; 2000 Mar 08; 108(4):805-16. PubMed ID: 10792287
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R.
    Cancer Res; 2002 Oct 15; 62(20):5845-52. PubMed ID: 12384547
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
    Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, Raymakers R, Schaap N, Dolstra H.
    Cancer Immunol Immunother; 2013 Aug 15; 62(8):1381-92. PubMed ID: 23728352
    [Abstract] [Full Text] [Related]

  • 17. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
    Qazilbash MH, Saini NY, Cha SC, Wang Z, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura S, Zhang T, Anderson A, Bashir Q, Shpall EJ, Orlowski RZ, Levine BL, Kerr N, Garfall A, Cohen A, Vogl DT, Dengel K, June CH, Champlin R, Kwak LW.
    Blood; 2022 Mar 03; 139(9):1289-1301. PubMed ID: 34521108
    [Abstract] [Full Text] [Related]

  • 18. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.
    Kitawaki T, Kadowaki N, Kondo T, Ishikawa T, Ichinohe T, Teramukai S, Fukushima M, Kasai Y, Maekawa T, Uchiyama T.
    Am J Hematol; 2008 Apr 03; 83(4):315-7. PubMed ID: 18081032
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.
    Höltl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, Nussbaumer W, Falkensammer C, Bartsch G, Thurnher M.
    Cancer Immunol Immunother; 2005 Jul 03; 54(7):663-70. PubMed ID: 15918076
    [Abstract] [Full Text] [Related]

  • 20. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM, Levy R.
    J Immunol; 2000 May 01; 164(9):4797-803. PubMed ID: 10779787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.